Chemistry:SYT-510
From HandWiki
SYT-510 is an endocannabinoid reuptake inhibitor, or "selective endocannabinoid reuptake inhibitor" ("SERI"), which is under development for the treatment of anxiety disorders, mood disorders, and traumatic stress disorders.[1][2][3][4] It is said to mildly and selectively increase levels of endocannabinoids like anandamide via inhibition of a newly identified biological target.[4][1] As of January 2024, the drug is in the preclinical stage of development or is entering phase 1 clinical trials for the preceding indications.[1][2][4][3] It is under development by a pharmaceutical company called Synendos Therapeutics.[1][2][3]
References
- ↑ 1.0 1.1 1.2 1.3 "SYT 510". 22 January 2024. https://adisinsight.springer.com/drugs/800061198.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on SYT-510 with Synapse". 4 August 2024. https://synapse.patsnap.com/drug/0724b1c676db4c55bf75d3c018531f67.
- ↑ 3.0 3.1 3.2 "CNS Drug Discovery in Academia: Where Basic Research Meets Innovation". ChemBioChem. July 2024. doi:10.1002/cbic.202400397. PMID 38958639. "Five years after incorporation, Synendos Therapeutics has completed non-clinical development of the [selective endocannabinoid reuptake inhibitor (SERI)] drug candidate SYT-510 and has initiated Phase 1 clinical development in healthy volunteers, marking the significant transition into a clinical stage biotech company. The mission of Synendos is to develop breakthrough safe and effective therapies for neurological and neuropsychiatric disorders through modulation of the [endocannabinoid system (ECS)] with SERIs to enable restoration of the natural functioning of the brain.".
- ↑ 4.0 4.1 4.2 Therapeutics, Synendos (18 January 2024). "Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510". https://www.prnewswire.com/news-releases/synendos-therapeutics-ag-granted-ema-clinical-trial-authorisation-for-first-in-class-endocannabinoid-system-modulator-syt-510-302037349.html.
External links
